Teprotumumab for active thyroid eye disease
Treatments studied
Part of Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a drug called teprotumumab for people with active thyroid eye disease. It is designed to help reduce eye bulging and other symptoms, and may be an option if you have not had strong treatments before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You weigh between 99 and 220 pounds.
- You have active thyroid eye disease that started within the last year, with bulging eyes of at least 16 millimeters.
- You have not already had a high dose of steroids or other specific treatments for this condition.
- You have no hearing loss or poorly controlled diabetes.
- You agree to use effective birth control during the study and for 4 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, KHN939, for people with moderate-to-severe active thyroid eye disease. It aims to reduce eye bulging and other symptoms.
This trial tests a new drug, KHN939, for people with moderate-to-severe thyroid eye disease that is no longer active. It aims to see if the drug can improve symptoms like bulging eyes, eyelid retraction, or double vision.
This trial tests a new version of an antibody treatment (teprotumumab) for people with active thyroid eye disease. It aims to reduce bulging and inflammation of the eyes, and you must have had symptoms for less than 9 months to join.
This study tests if the drug teprotumumab can help with symptoms of thyroid eye disease, such as bulging eyes, pain, or double vision. It is for adults who are beneficiaries of the Department of Defense (DOD).
This trial tests a new drug called NTB003 for people with moderate-to-severe thyroid eye disease (TED). It aims to see if the drug can improve symptoms like eye bulging and double vision, and it may be an option for those whose disease is active or has been ongoing for a while.
This study compares two different treatment plans for Thyroid Eye Disease (TED): the standard 8 infusions of Tepezza versus a shorter 4-infusion course. It aims to see if 4 treatments might work just as well and be safer, but only for people who already respond well after the first 4 doses.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.